NCT01873339 Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects Status COMPLETED Phase PHASE1
NCT01868035 Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP Status COMPLETED Phase PHASE2
NCT01868022 Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Status COMPLETED Phase PHASE1
NCT01868009 DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD) Status COMPLETED Phase PHASE3
NCT01867996 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ) Status COMPLETED Phase PHASE1
NCT01858831 Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension Status COMPLETED Phase PHASE1
NCT01858792 A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies Status COMPLETED Phase N/A
NCT01857895 Feasibility Study of Exenatide by Continuous Subcutaneous Infusion Status COMPLETED Phase PHASE1
NCT01857869 Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults Status COMPLETED Phase PHASE2
NCT01856309 Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 Status COMPLETED Phase PHASE3
NCT01855724 Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Status TERMINATED Phase PHASE2
NCT01855711 Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) Status COMPLETED Phase PHASE2
NCT01853878 A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor Status COMPLETED Phase PHASE2